| Title |
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery
|
|---|---|
| Published in |
Vascular Health and Risk Management, October 2013
|
| DOI | 10.2147/vhrm.s51244 |
| Pubmed ID | |
| Authors |
Yasufumi Kuroda, Chie Hirayama, Hitoshi Hotoda, Yasuhiro Nishikawa, Akinori Nishiwaki |
| Abstract |
Edoxaban is an oral, once-daily, selective, direct factor Xa inhibitor approved in Japan for the prevention of venous thromboembolism following major orthopedic surgery. Currently, edoxaban is in Phase III clinical development for the prevention of stroke and systemic embolic events in patients with atrial fibrillation, and for the treatment and prevention of recurrences of venous thromboembolism. This report describes the adverse drug reactions (ADRs) spontaneously reported during early postmarketing phase vigilance from the time of its commercial launch in Japan. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Portugal | 1 | 2% |
| Slovenia | 1 | 2% |
| Unknown | 59 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 23% |
| Other | 7 | 11% |
| Unspecified | 5 | 8% |
| Researcher | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Other | 17 | 27% |
| Unknown | 9 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 48% |
| Unspecified | 5 | 8% |
| Nursing and Health Professions | 4 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 11 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2013.
All research outputs
#17,285,036
of 25,371,288 outputs
Outputs from Vascular Health and Risk Management
#541
of 804 outputs
Outputs of similar age
#137,948
of 219,840 outputs
Outputs of similar age from Vascular Health and Risk Management
#15
of 19 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,840 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.